Cu­ria nets con­tract for cannabi­noid can­di­date and taps a new pres­i­dent of man­u­fac­tur­ing

The CD­MO Cu­ria, fresh off an ex­pan­sion a year ago, is scal­ing up man­u­fac­tur­ing for a can­di­date from an Aus­tralian biotech.

In­can­nex Health­care, a biotech cen­tered on pro­duc­ing cannabi­noid-based med­i­cines and psy­che­del­ic ther­a­pies, is us­ing Cu­ria Glob­al to fur­ther de­vel­op and man­u­fac­ture a GMP-grade in­haled drug prod­uct for the treat­ment of con­cus­sion and trau­mat­ic brain in­jury orig­i­nal­ly de­vel­oped by the biotech.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER